Brief: Cytodyn Reaches Enrollment Target Of 293 Patients For 2nd Interim Analysis Of Phase 3 COVID-19 Trial
23/11/2020 12:02
Nov 23 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN REACHES ENROLLMENT TARGET OF 293 PATIENTS FOR 2ND
DSMC
INTERIM ANALYSIS OF PHASE 3 COVID-19 TRIAL AND EXPECTS TO ENROLL
THE REMAINING 97 PATIENTS IN THE NEXT FEW WEEKS TO COMPLETE THE
TRIAL THIS YEAR
Source text for Eikon: ID:nGNXbZZ53b
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer